Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that its CEO, Mark Gergen, will participate in a fireside chat during the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that its CEO, Mark Gergen, will participate in a fireside chat during the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET. The event focuses on advancements in cell and gene therapies for cancer and rare diseases. Investors can access a live webcast of the presentation on Poseida's website, with a replay available for 90 days post-event. Poseida is recognized for its proprietary genetic editing platforms aimed at improving patient outcomes in oncology.
Details
News Market Reaction – PSTX
The recorded move for PSTX in the trading session of this news was +2.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.
A webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Poseida's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral Super piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed global strategic collaborations with Roche and Takeda to unlock the promise of cell and gene therapies for patients. Learn more at www.poseida.com and connect with Poseida on Twitter and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-cell-therapy-virtual-conference-301746302.html
SOURCE Poseida Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.